Getting a new drug approved by the FDA can take years. Unfortunately, that can prevent patients from accessing some of the most innovative treatments.
Recently, though, the FDA created the Fast Track program. Fast Track lets companies meet with regulators more frequently and take advantage of other perks that can get drugs to patients sooner.
Fast Track is an essential update to the approval process, especially now that artificial intelligence has accelerated drug discovery and testing. The change, however, will put some pressure on companies, often forcing them to reconsider biotech hiring trends to ensure they always have the right people in the right positions.
The Acceleration Imperative
In the summer of 2025, the FDA announced a series of priorities for the upcoming year. Those priorities include accelerating drug development, using AI for scientific review, and harnessing real-world data for validation.
The overall goal is to research, develop, and test more treatments within shorter timeframes. This will benefit the public and, ideally, reduce long-term healthcare costs. It also has major implications for small and new businesses in the biotech sector.
By integrating AI into every phase, companies can significantly lower their pre-market costs. It’s much cheaper to let AI discover novel compounds than to do the job manually in a lab.
Lowering these costs should heighten risk tolerance in startups. That means you can expect to see more small businesses entering the biotech sector, where they’ll lead innovations that revolutionize healthcare.
Talent Implications: Compliance Meets Agility
Traditionally, the biotech workforce strategy has concentrated on finding professionals with years of research experience. They did the “heavy lifting” needed to discover and test new treatments. Now that AI can do much of that work more quickly, companies will need to adopt a new biotech workforce strategy that emphasizes cross-functional positions.
For example, companies will likely move toward hiring more professionals with diverse experience in areas like regulations, quality assurance, and commercialization. Knowing one side of the equation isn’t enough anymore. Top hires will understand pharmaceutical science and policy.
As a result, expect to see more hybrid roles like:
- Regulatory data scientist
- Clinical AI validation lead
- Digital compliance officer
The industry is changing fast, and firms need to adapt to the emerging landscape to remain competitive.
Market Effects on Talent Strategy
Not surprisingly, these rapid changes are influencing talent fulfillment strategies. Up until recently, your company might have relied on professionals who filled specific roles. You probably hired individuals for each of these titles…
- Clinical research physician
- Clinical research lead
- Research lab tech
- Clinical development director
- Computational biologist
- Patent specialist
- Regulatory supervisor
While these are still critical jobs, market changes have shifted industry expectations when it comes to finding people to fill them.
It’s increasingly unlikely that you want someone who only focuses in filing for patents or researching new drugs. Instead, your top-choice candidate is someone who can research new drugs and understand the patenting process. That way, you can develop products, get them approved, and have them on the market as soon as possible.
In many places, mergers and acquisitions have fueled this change. Instead of starting new businesses, owners are likely to merge existing structures. It’s a relatively simple way to build experienced groups that get results.
Even if you take that approach, though, you’ll find some gaps. There simply aren’t that many people who have the right levels of experience in multiple areas of pharmacological research.
Recruiting Outlook: How to Hire for Speed and Safety
Recruiters and hiring leaders should be looking for adaptability, risk literacy, and multi-disciplinary communication in 2026. It’s also important to remember that traditional hiring cycles may no longer fit accelerated product timelines.
Recruits who can fill multiple roles stand out as top candidates, especially when they can step in and get to work immediately.
Conclusion: Building the 2026 BioTech Workforce
Building the 2026 biotech workforce will require new strategies. That’s where MRINetwork can help.
We specialize in finding and vetting skilled professionals who can begin working for your company quickly, while you remain focused on researching and developing new treatments.
Connect with an MRINetwork office near you to find job candidates ready for today’s growing industry.
Connect with MRINetwork